- Stocks
- Pharma & Healthcare
- BALAXI PHARMACEUTICALS
BALAXI PHARMACEUTICALS share price
NSE: BALAXIPharma & HealthcareDrug Manufacturers - Specialty & Generic
BALAXI PHARMACEUTICALS at a glance
BALAXI PHARMACEUTICALS (NSE: BALAXI) closed at ₹20.31 on 22 Oct 2026, down 4.65% on the day. With a market capitalisation of ₹112 Cr, it ranks 2598th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 78.1× trailing earnings, against a return on equity of 0.6% in FY26. Over the past year the share price has fallen 52.7%. Its 52-week range is ₹15.20 (27 Mar 2026) to ₹43.85 (4 Nov 2025); the last close is 53.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹81 Cr (+14.1% year on year) and net profit ₹1 Cr (+348.3%), on a consolidated basis. Promoters held 65.99% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹112 CrRank 2598 on NSE
- P/E (trailing)
- 78.1×
- Price to book
- 0.35×FY26
- EPS (TTM)
- ₹0.45to Q1 FY27
- ROE
- 0.6%FY26
- ROCE
- 3.1%FY26
- Debt to equity
- 0.22FY26
- Net profit margin
- 0.5%FY26
- Book value / share
- ₹45.12FY26
- 52-week high
- ₹43.854 Nov 2025
- 52-week low
- ₹15.2027 Mar 2026
- 1-year return
- −52.7%
- RSI (14-day)
- 29.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −4.65% | −8.4% | −13.6% | −16.0% | −52.7% |
BALAXI PHARMACEUTICALS quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹77 Cr | ₹73 Cr | ₹76 Cr | ₹71 Cr | ₹56 Cr | ₹73 Cr | ₹71 Cr | ₹81 Cr |
| Revenue YoY | +41.4% | +20.6% | +27.5% | +7.8% | −27.4% | −1.0% | −7.3% | +14.1% |
| Net profit | ₹5 Cr | ₹5 Cr | ₹9 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr |
| Net profit YoY | −68.2% | −60.6% | −21.0% | −95.5% | −95.4% | −94.2% | −92.9% | +348.3% |
| Net margin | 5.9% | 7.3% | 11.3% | 0.4% | 0.4% | 0.4% | 0.9% | 1.6% |
| EPS | ₹0.84 | ₹0.97 | ₹1.56 | ₹0.05 | ₹0.04 | ₹0.06 | ₹0.11 | ₹0.24 |
BALAXI PHARMACEUTICALS financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹231 Cr | ₹279 Cr | ₹336 Cr | ₹241 Cr | ₹293 Cr | — |
| Operating profit | ₹44 Cr | ₹55 Cr | ₹57 Cr | ₹40 Cr | ₹29 Cr | — |
| Net profit | ₹38 Cr | ₹48 Cr | ₹46 Cr | −₹2 Cr | ₹25 Cr | — |
| EPS (₹) | ₹38.00 | ₹48.00 | ₹46.00 | −₹2.00 | ₹5.00 | — |
| Cash from operations | ₹0 Cr | ₹34 Cr | ₹6 Cr | ₹5 Cr | −₹35 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹21 Cr | ₹22 Cr |
| Shareholders' equity | ₹65 Cr | ₹113 Cr | ₹183 Cr | ₹201 Cr | ₹232 Cr | ₹249 Cr |
BALAXI PHARMACEUTICALS shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% |
| Foreign institutions | 16.02% | 8.87% | 3.50% | 1.74% | 0.00% | 0.00% |
| Domestic institutions | 0.02% | 0.02% | 0.02% | 0.02% | 2.56% | 2.56% |
| Non-institutions | 17.96% | 25.12% | 30.49% | 32.24% | 31.45% | 31.45% |
BALAXI PHARMACEUTICALS vs peers
The listed Pharma & Healthcare companies nearest to BALAXI PHARMACEUTICALS by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KREBSBIOKrebs Biochemicals and Industries | ₹56.59 | +0.78% | −19.3% | ₹122 Cr | — | — |
| GODAVARIGodavari Drugs | — | — | — | ₹120 Cr | — | — |
| PARNAXLABParnax Lab | ₹104.00 | −4.54% | — | ₹119 Cr | 10.1 | — |
| MAKERSLMakers Labs | ₹191.02 | −3.53% | — | ₹113 Cr | 48 | — |
| PHARMAIDPharmaids Pharm | — | — | — | ₹113 Cr | — | — |
| BALAXIBALAXI PHARMACEUTICALS | ₹20.31 | −4.65% | −52.7% | ₹112 Cr | 78.1 | — |
| ALPAAlpa Laboratories | ₹51.70 | +0.90% | −41.8% | ₹109 Cr | 7.3 | — |
Ask anything about BALAXI PHARMACEUTICALS
Pivot answers on the live chart with evidence you can check, and tests strategies against BALAXI's own history. Try: “Why has BALAXI moved over the last three months?” · “Backtest a 50-day moving-average crossover on BALAXI over five years” · “Compare BALAXI with KREBSBIO on margins and valuation”
Frequently asked questions about BALAXI PHARMACEUTICALS
What is the share price of BALAXI PHARMACEUTICALS today?
BALAXI PHARMACEUTICALS (NSE: BALAXI) last closed at ₹20.31 on 22 Oct 2026. Its 52-week high is ₹43.85 and its 52-week low is ₹15.20.
What is the market cap of BALAXI PHARMACEUTICALS?
BALAXI PHARMACEUTICALS's market capitalisation is ₹112 Cr (₹112 Cr) at the 22 Oct 2026 close, ranking 2598th among the NSE companies Pivot tracks.
What is the P/E ratio of BALAXI PHARMACEUTICALS?
BALAXI PHARMACEUTICALS trades at a trailing P/E of 78.1. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 10.1.
What is the ROE and ROCE of BALAXI PHARMACEUTICALS?
Return on equity was 0.6% in FY26 and return on capital employed was 3.1% in FY26 (consolidated figures).
Is BALAXI PHARMACEUTICALS a debt-free company?
No. BALAXI PHARMACEUTICALS's debt-to-equity ratio was 0.22 in FY26, with total debt of ₹22 Cr.
What were BALAXI PHARMACEUTICALS's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), BALAXI PHARMACEUTICALS reported revenue of ₹81 Cr, +14.1% year on year, and net profit of ₹1 Cr, +348.3% year on year.
How has BALAXI PHARMACEUTICALS stock performed over the last year?
BALAXI PHARMACEUTICALS's share price has fallen 52.7% over the past year, −16.0% over three months and −13.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of BALAXI PHARMACEUTICALS?
As of 30 Jun 2026: promoters 65.99%, foreign institutions 0.00%, domestic institutions 2.56%, non-institutions 31.45%.
Who are BALAXI PHARMACEUTICALS's competitors?
The listed Pharma & Healthcare companies closest to BALAXI PHARMACEUTICALS by market cap are Krebs Biochemicals and Industries, Godavari Drugs, Parnax Lab, Makers Labs, Pharmaids Pharm and Alpa Laboratories.
Is BALAXI PHARMACEUTICALS a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out BALAXI PHARMACEUTICALS's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BALAXI against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text